Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +49.85%
#3 DOVU DOVU +47.86%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.36%
#6 Cross Cross +21.02%
#7 Perle Perle +19.03%
#8 τemplar τemplar +16.86%
#9 Cysic Cysic +15.93%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.88%
Coin of the day
Glidr Glidr
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Classement en actions #38382
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Prix de l'action
$0.02468497
Capitalisation boursière
$1.01M
Changement (1 jour)
-12.50%
Changement (1 an)
-87.34%
Pays
AU
Échange Chimeric Therapeutics Limited (CHM)

Catégorie

Healthcare
EPS pour Chimeric Therapeutics Limited (CHM)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Chimeric Therapeutics Limited, l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Chimeric Therapeutics Limited de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE